Cargando…

Age-Stratified Seroprevalence of SARS-CoV-2 Antibodies before and during the Vaccination Era, Japan, February 2020–March 2022

Japan has reported a relatively small number of COVID-19 cases. Because not all infected persons receive diagnostic tests for COVID-19, the reported number must be lower than the actual number of infections. We assessed SARS-CoV-2 seroprevalence by analyzing >60,000 samples collected in Japan (To...

Descripción completa

Detalles Bibliográficos
Autores principales: Yamayoshi, Seiya, Iwatsuki-Horimoto, Kiyoko, Okuda, Moe, Ujie, Michiko, Yasuhara, Atsuhiro, Murakami, Jurika, Duong, Calvin, Hamabata, Taiki, Ito, Mutsumi, Chiba, Shiho, Kobayashi, Ryo, Takahashi, Satoshi, Mitamura, Keiko, Hagihara, Masao, Shibata, Akimichi, Uwamino, Yoshifumi, Hasegawa, Naoki, Ebina, Toshiaki, Izumi, Akihiko, Kato, Hideaki, Nakajima, Hideaki, Sugaya, Norio, Seki, Yuki, Iqbal, Asef, Kamimaki, Isamu, Yamazaki, Masahiko, Kawaoka, Yoshihiro, Furuse, Yuki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Centers for Disease Control and Prevention 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9622230/
https://www.ncbi.nlm.nih.gov/pubmed/36198306
http://dx.doi.org/10.3201/eid2811.221127
_version_ 1784821714554716160
author Yamayoshi, Seiya
Iwatsuki-Horimoto, Kiyoko
Okuda, Moe
Ujie, Michiko
Yasuhara, Atsuhiro
Murakami, Jurika
Duong, Calvin
Hamabata, Taiki
Ito, Mutsumi
Chiba, Shiho
Kobayashi, Ryo
Takahashi, Satoshi
Mitamura, Keiko
Hagihara, Masao
Shibata, Akimichi
Uwamino, Yoshifumi
Hasegawa, Naoki
Ebina, Toshiaki
Izumi, Akihiko
Kato, Hideaki
Nakajima, Hideaki
Sugaya, Norio
Seki, Yuki
Iqbal, Asef
Kamimaki, Isamu
Yamazaki, Masahiko
Kawaoka, Yoshihiro
Furuse, Yuki
author_facet Yamayoshi, Seiya
Iwatsuki-Horimoto, Kiyoko
Okuda, Moe
Ujie, Michiko
Yasuhara, Atsuhiro
Murakami, Jurika
Duong, Calvin
Hamabata, Taiki
Ito, Mutsumi
Chiba, Shiho
Kobayashi, Ryo
Takahashi, Satoshi
Mitamura, Keiko
Hagihara, Masao
Shibata, Akimichi
Uwamino, Yoshifumi
Hasegawa, Naoki
Ebina, Toshiaki
Izumi, Akihiko
Kato, Hideaki
Nakajima, Hideaki
Sugaya, Norio
Seki, Yuki
Iqbal, Asef
Kamimaki, Isamu
Yamazaki, Masahiko
Kawaoka, Yoshihiro
Furuse, Yuki
author_sort Yamayoshi, Seiya
collection PubMed
description Japan has reported a relatively small number of COVID-19 cases. Because not all infected persons receive diagnostic tests for COVID-19, the reported number must be lower than the actual number of infections. We assessed SARS-CoV-2 seroprevalence by analyzing >60,000 samples collected in Japan (Tokyo Metropolitan Area and Hokkaido Prefecture) during February 2020–March 2022. The results showed that ≈3.8% of the population had become seropositive by January 2021. The seroprevalence increased with the administration of vaccinations; however, among the elderly, seroprevalence was not as high as the vaccination rate. Among children, who were not eligible for vaccination, infection was spread during the epidemic waves caused by the SARS-CoV-2 Delta and Omicron variants. Nevertheless, seroprevalence for unvaccinated children <5 years of age was as low as 10% as of March 2022. Our study underscores the low incidence of SARS-CoV-2 infection in Japan and the effects of vaccination on immunity at the population level.
format Online
Article
Text
id pubmed-9622230
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Centers for Disease Control and Prevention
record_format MEDLINE/PubMed
spelling pubmed-96222302022-11-05 Age-Stratified Seroprevalence of SARS-CoV-2 Antibodies before and during the Vaccination Era, Japan, February 2020–March 2022 Yamayoshi, Seiya Iwatsuki-Horimoto, Kiyoko Okuda, Moe Ujie, Michiko Yasuhara, Atsuhiro Murakami, Jurika Duong, Calvin Hamabata, Taiki Ito, Mutsumi Chiba, Shiho Kobayashi, Ryo Takahashi, Satoshi Mitamura, Keiko Hagihara, Masao Shibata, Akimichi Uwamino, Yoshifumi Hasegawa, Naoki Ebina, Toshiaki Izumi, Akihiko Kato, Hideaki Nakajima, Hideaki Sugaya, Norio Seki, Yuki Iqbal, Asef Kamimaki, Isamu Yamazaki, Masahiko Kawaoka, Yoshihiro Furuse, Yuki Emerg Infect Dis Research Japan has reported a relatively small number of COVID-19 cases. Because not all infected persons receive diagnostic tests for COVID-19, the reported number must be lower than the actual number of infections. We assessed SARS-CoV-2 seroprevalence by analyzing >60,000 samples collected in Japan (Tokyo Metropolitan Area and Hokkaido Prefecture) during February 2020–March 2022. The results showed that ≈3.8% of the population had become seropositive by January 2021. The seroprevalence increased with the administration of vaccinations; however, among the elderly, seroprevalence was not as high as the vaccination rate. Among children, who were not eligible for vaccination, infection was spread during the epidemic waves caused by the SARS-CoV-2 Delta and Omicron variants. Nevertheless, seroprevalence for unvaccinated children <5 years of age was as low as 10% as of March 2022. Our study underscores the low incidence of SARS-CoV-2 infection in Japan and the effects of vaccination on immunity at the population level. Centers for Disease Control and Prevention 2022-11 /pmc/articles/PMC9622230/ /pubmed/36198306 http://dx.doi.org/10.3201/eid2811.221127 Text en https://creativecommons.org/licenses/by/4.0/Emerging Infectious Diseases is a publication of the U.S. Government. This publication is in the public domain and is therefore without copyright. All text from this work may be reprinted freely. Use of these materials should be properly cited.
spellingShingle Research
Yamayoshi, Seiya
Iwatsuki-Horimoto, Kiyoko
Okuda, Moe
Ujie, Michiko
Yasuhara, Atsuhiro
Murakami, Jurika
Duong, Calvin
Hamabata, Taiki
Ito, Mutsumi
Chiba, Shiho
Kobayashi, Ryo
Takahashi, Satoshi
Mitamura, Keiko
Hagihara, Masao
Shibata, Akimichi
Uwamino, Yoshifumi
Hasegawa, Naoki
Ebina, Toshiaki
Izumi, Akihiko
Kato, Hideaki
Nakajima, Hideaki
Sugaya, Norio
Seki, Yuki
Iqbal, Asef
Kamimaki, Isamu
Yamazaki, Masahiko
Kawaoka, Yoshihiro
Furuse, Yuki
Age-Stratified Seroprevalence of SARS-CoV-2 Antibodies before and during the Vaccination Era, Japan, February 2020–March 2022
title Age-Stratified Seroprevalence of SARS-CoV-2 Antibodies before and during the Vaccination Era, Japan, February 2020–March 2022
title_full Age-Stratified Seroprevalence of SARS-CoV-2 Antibodies before and during the Vaccination Era, Japan, February 2020–March 2022
title_fullStr Age-Stratified Seroprevalence of SARS-CoV-2 Antibodies before and during the Vaccination Era, Japan, February 2020–March 2022
title_full_unstemmed Age-Stratified Seroprevalence of SARS-CoV-2 Antibodies before and during the Vaccination Era, Japan, February 2020–March 2022
title_short Age-Stratified Seroprevalence of SARS-CoV-2 Antibodies before and during the Vaccination Era, Japan, February 2020–March 2022
title_sort age-stratified seroprevalence of sars-cov-2 antibodies before and during the vaccination era, japan, february 2020–march 2022
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9622230/
https://www.ncbi.nlm.nih.gov/pubmed/36198306
http://dx.doi.org/10.3201/eid2811.221127
work_keys_str_mv AT yamayoshiseiya agestratifiedseroprevalenceofsarscov2antibodiesbeforeandduringthevaccinationerajapanfebruary2020march2022
AT iwatsukihorimotokiyoko agestratifiedseroprevalenceofsarscov2antibodiesbeforeandduringthevaccinationerajapanfebruary2020march2022
AT okudamoe agestratifiedseroprevalenceofsarscov2antibodiesbeforeandduringthevaccinationerajapanfebruary2020march2022
AT ujiemichiko agestratifiedseroprevalenceofsarscov2antibodiesbeforeandduringthevaccinationerajapanfebruary2020march2022
AT yasuharaatsuhiro agestratifiedseroprevalenceofsarscov2antibodiesbeforeandduringthevaccinationerajapanfebruary2020march2022
AT murakamijurika agestratifiedseroprevalenceofsarscov2antibodiesbeforeandduringthevaccinationerajapanfebruary2020march2022
AT duongcalvin agestratifiedseroprevalenceofsarscov2antibodiesbeforeandduringthevaccinationerajapanfebruary2020march2022
AT hamabatataiki agestratifiedseroprevalenceofsarscov2antibodiesbeforeandduringthevaccinationerajapanfebruary2020march2022
AT itomutsumi agestratifiedseroprevalenceofsarscov2antibodiesbeforeandduringthevaccinationerajapanfebruary2020march2022
AT chibashiho agestratifiedseroprevalenceofsarscov2antibodiesbeforeandduringthevaccinationerajapanfebruary2020march2022
AT kobayashiryo agestratifiedseroprevalenceofsarscov2antibodiesbeforeandduringthevaccinationerajapanfebruary2020march2022
AT takahashisatoshi agestratifiedseroprevalenceofsarscov2antibodiesbeforeandduringthevaccinationerajapanfebruary2020march2022
AT mitamurakeiko agestratifiedseroprevalenceofsarscov2antibodiesbeforeandduringthevaccinationerajapanfebruary2020march2022
AT hagiharamasao agestratifiedseroprevalenceofsarscov2antibodiesbeforeandduringthevaccinationerajapanfebruary2020march2022
AT shibataakimichi agestratifiedseroprevalenceofsarscov2antibodiesbeforeandduringthevaccinationerajapanfebruary2020march2022
AT uwaminoyoshifumi agestratifiedseroprevalenceofsarscov2antibodiesbeforeandduringthevaccinationerajapanfebruary2020march2022
AT hasegawanaoki agestratifiedseroprevalenceofsarscov2antibodiesbeforeandduringthevaccinationerajapanfebruary2020march2022
AT ebinatoshiaki agestratifiedseroprevalenceofsarscov2antibodiesbeforeandduringthevaccinationerajapanfebruary2020march2022
AT izumiakihiko agestratifiedseroprevalenceofsarscov2antibodiesbeforeandduringthevaccinationerajapanfebruary2020march2022
AT katohideaki agestratifiedseroprevalenceofsarscov2antibodiesbeforeandduringthevaccinationerajapanfebruary2020march2022
AT nakajimahideaki agestratifiedseroprevalenceofsarscov2antibodiesbeforeandduringthevaccinationerajapanfebruary2020march2022
AT sugayanorio agestratifiedseroprevalenceofsarscov2antibodiesbeforeandduringthevaccinationerajapanfebruary2020march2022
AT sekiyuki agestratifiedseroprevalenceofsarscov2antibodiesbeforeandduringthevaccinationerajapanfebruary2020march2022
AT iqbalasef agestratifiedseroprevalenceofsarscov2antibodiesbeforeandduringthevaccinationerajapanfebruary2020march2022
AT kamimakiisamu agestratifiedseroprevalenceofsarscov2antibodiesbeforeandduringthevaccinationerajapanfebruary2020march2022
AT yamazakimasahiko agestratifiedseroprevalenceofsarscov2antibodiesbeforeandduringthevaccinationerajapanfebruary2020march2022
AT kawaokayoshihiro agestratifiedseroprevalenceofsarscov2antibodiesbeforeandduringthevaccinationerajapanfebruary2020march2022
AT furuseyuki agestratifiedseroprevalenceofsarscov2antibodiesbeforeandduringthevaccinationerajapanfebruary2020march2022